ImmunoGen

IMGN NASDAQ
2.730
-0.120
-4.21%
After Hours: 2.730 0 0.00% 16:36 08/20 EDT
Open
2.830
Prev Close
2.850
High
2.860
Low
2.680
Volume
969.57K
Avg Vol (3M)
2.86M
52 Week High
10.37
52 Week Low
1.760
% Turnover
0.65%
Market Cap
409.19M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers ImmunoGen IMGN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
MORE >

Recently

Name
Price
%Change